Dr Bruno Paiva speaks to ecancer about novel biomarkers in myeloma: CTCs and cfDNA.

Current advancements in circulating tumour cells and DNA in multiple myeloma focus on the prognostic value of biomarkers.

There is a push for consensus and clinical application, especially from the International Myeloma Working Group.

New detection technologies, like the next-generation flow assay, enhance CTC quantification.

As patient longevity increases, effective monitoring strategies become crucial, highlighting the need for minimally invasive assessments and integrating biomarkers into routine practices.